Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.
For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...
A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward ...
Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...